Compare BridgeBio Pharma Inc (BBIO) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Bill.com Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Bill.com Holdings Inc trades at $49.45 (market cap $4.91B). The key difference: BridgeBio Pharma Inc is far larger — about 3.4× Bill.com Holdings Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | BILL | |
|---|---|---|
Market Cap | $16.61B | $4.91B |
Sector | Health | Technology |
52-Week High | $90.17 | $56.32 |
52-Week Low | $47.29 | $31.96 |
Enterprise Value | $18.16B | $4.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BILL Holdings trades at $47.99, up 2.11% today, with a bullish technical signal from moving averages and strong institutional interest. The company reported revenue growth to $1.46B in 2025 and achieved profitability with net income of $23.80M, marking a significant turnaround from prior losses. Recent news highlights operational efficiency gains from a 30% workforce reduction and strategic focus on AI-driven financial automation for SMBs.
The outlook is positive with consistent earnings beats and analyst consensus favoring a buy rating, though high P/E of 213.91 indicates premium valuation. Key risks include intense fintech competition and reliance on SMB market stability. Upside to the $50.00 high price target depends on sustained margin expansion and successful AI integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
